Published • loading... • Updated
Artera Expands Its Validated Multimodal AI Platform to Metastatic Hormone‑Sensitive Prostate Cancer (mHSPC)
Summary by Daily-tribune.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
New AI Test Predicts Mortality Risk in Metastatic Prostate Cancer
The digital pathology platform provides patient-specific risk estimates to help clinicians tailor treatment for metastatic hormone-sensitive disease. Artera announced the clinical availability of the ArteraAI Prostate Test, a digital pathology-based prognostic test designed to help inform treatment planning for patients with metastatic hormone-sensitive prostate cancer (mHSPC). The disease state of mHSPC often involves variable outcomes and comp…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
